Evidence map›Paper›PMID 35113225›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.

Hironobu Hata, Kenji Imamachi, Michihiro Ueda, Masashi Matsuzaka, Hiroaki Hiraga, Toshihisa Osanai, Toru Harabayashi, Katsuya Fujimoto, Satoshi Oizumi, Masato Takahashi and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. [Expert consensus on perioperative management of tooth extraction in patients receiving denosumab therapy].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026
    Article
  4. Article
  5. Efficacy and risks of drug holiday in the management of medication-related osteonecrosis of the jaw in cancer patients: a single-center retrospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Hironobu HataDepartment of Dentistry and Oral Surgery, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan. hata.hironobu.wq@mail.hosp.go.jp.ORCID http://orcid.org/0000-0002-0077-7026
Kenji ImamachiDepartment of Dentistry and Oral Surgery, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan.ORCID http://orcid.org/0000-0003-1090-3660
Michihiro UedaDepartment of Clinical Oral Oncology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-jo 2-chome, Shiroishi-Ku, Sapporo, 003-0804, Japan.
Masashi MatsuzakaClinical Research Support Centre, Hirosaki University Hospital, 53 Honcho, Hirosaki, 036-8563, Japan.ORCID http://orcid.org/0000-0002-8199-3037
Hiroaki HiragaDepartment of Orthopaedic Surgery, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan.
Toshihisa OsanaiDepartment of Rehabilitation, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan.ORCID http://orcid.org/0000-0003-0220-0535
Toru HarabayashiDepartment of Urology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan.
Katsuya FujimotoDepartment of Hematology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan.
Satoshi OizumiDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan.
Masato TakahashiDepartment of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan.ORCID http://orcid.org/0000-0002-6641-9598
Kazuhito YoshikawaOral Diagnosis and Medicine, Department of Oral Pathobiological Science, Faculty of Dental Medicine, Hokkaido University, Nishi 7-Tyoume Kita13-Jyo, Kita-Ku, Sapporo, 060-8586, Japan.
Jun SatoOral Diagnosis and Medicine, Department of Oral Pathobiological Science, Faculty of Dental Medicine, Hokkaido University, Nishi 7-Tyoume Kita13-Jyo, Kita-Ku, Sapporo, 060-8586, Japan.
Yutaka YamazakiGerodontology Department of Oral Health Science, Faculty of Dental Medicine, Hokkaido University, Nishi 7-Tyoume Kita13-Jyo, Kita-Ku, Sapporo, 060-8586, Japan.
Yoshimasa KitagawaOral Diagnosis and Medicine, Department of Oral Pathobiological Science, Faculty of Dental Medicine, Hokkaido University, Nishi 7-Tyoume Kita13-Jyo, Kita-Ku, Sapporo, 060-8586, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSurvival time after bisphosphonate use has been increasingly recognized to be associated with the incidence of medication-related osteonecrosis of the jaw (MRONJ); however, this has not been elucidated sufficiently in the literature. This study aimed to clarify the incidence of MRONJ and the corresponding survival rate of patients treated with zoledronic acid (ZA) for each type of cancer and obtain useful information for the oral/dental supportive care of cancer patients.

methodsWe evaluated 988 patients who were administered ZA at our hospital; among them, 862 patients with metastatic bone tumors or myeloma were included.

resultsThe median survival time (MST) after ZA initiation was 35, 34, 8, 41, 12, and 6 months for patients with breast, prostrate, lung, myeloma, renal, and other cancers, respectively. Patients with cancers that had a short survival time (lung and other cancers [MST = 8 and 6 months, respectively] and cancers with MST < 10 months) did not develop MRONJ; this could be attributed to the shorter duration of ZA administration. The cumulative incidence of MRONJ in breast cancer, prostate cancer, and multiple myeloma was related to the frequency of anti-resorptive drug use and the increased risk over time. In renal cancer, the cumulative incidence of MRONJ increased early, although the MST was 12 months.

conclusionFor the dentists in charge of dental management, it is essential to be aware of prognosis-related factors, predict MRONJ risk for each cancer treatment, and use risk prediction in dental management planning, particularly for cancers with non-poor prognosis.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsBone NeoplasmsDenosumabDiphosphonatesHumansIncidenceMalePrognosisRetrospective StudiesZoledronic AcidBone Density Conservation AgentsDenosumabDiphosphonatesZoledronic AcidBisphosphonatesJawOsteonecrosisPrognosis

Identifiers

PMID35113225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.